Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FSHR | P23945 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14854850 | 0.79 | TSHR (0.43) | NFKB1NFKB2RELAMAPKAPK2MAP4K4 | |
| SCHEMBL25274470 | 0.79 | AAK1 (0.41) | NFKB1NFKB2RELAMAPKAPK2MAP4K4 | |
| SCHEMBL24756661 | 0.72 | MAPKAPK2 (0.44) | MAPKAPK2STK17BSTK17ACSNK1D | |
| SCHEMBL22234711 | 0.71 | GAA (0.45) | TSHRFSHRTRPA1RAB9A | |
| SCHEMBL101218 | 0.71 | DGAT1 (0.46) | NFKB1NFKB2RELA | |
| SCHEMBL28048189 | 0.70 | CYP19A1 (0.36) | TSHR | |
| SCHEMBL22778721 | 0.69 | GAA (0.47) | RAB9A | |
| SCHEMBL7159196 | 0.69 | ALDH1A1 (0.37) | — | |
| SCHEMBL56219 | 0.69 | PTGS1 (0.50) | MAPKAPK2MAP4K4ATRRAB9A | |
| SCHEMBL23204225 | 0.69 | ADORA2A (0.47) | STK17BSTK17ACSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | NFKB1 39/4885NFKB2 149/4885RELA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.